Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11247509 | 0.77 | LMNA (0.58) | MAOBFDFT1 | |
| SCHEMBL9113408 | 0.74 | ACACB (0.48) | — | |
| SCHEMBL27038509 | 0.72 | PARP15 (0.37) | — | |
| SCHEMBL27037290 | 0.72 | ALOX5 (0.44) | WDR5MAOBALOX5PRMT5 | |
| SCHEMBL27038811 | 0.72 | GAA (0.49) | WDR5MAOBALOX5 | |
| SCHEMBL27038331 | 0.72 | PIK3CA (0.42) | — | |
| SCHEMBL9114079 | 0.70 | CYP3A4 (0.46) | FFAR1ALOX5 | |
| SCHEMBL21914530 | 0.70 | AOC3 (0.59) | MAOBALOX5FDFT1PRMT5 | |
| SCHEMBL25835186 | 0.69 | AOC3 (0.57) | MAOBALOX5FDFT1PRMT5 | |
| SCHEMBL21889546 | 0.68 | AOC3 (0.61) | MAOBFDFT1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649062-B1 | BICYCLIC COMPOUNDS AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | TAKEDA PHARMACEUTICAL (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-8729102-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142714-A1 | BICYCLIC COMPOUND | ACACA, ACACB, FABP4 | FFAR1 683/4885WDR5 394/4885MAOB 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.